24/7 Wall Street
23 Jan 2026, 19:06 UTC · 35w ago
Verdict
Headline takes no side. We score ALT +1.00 across three claims — strongly bullish.
+1.00strongly bullish
More positive than 99% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
The FDA granted Breakthrough Therapy Designation for Altimmune's lead drug pemvidutide on January 16.
More positive than 99% of claims this week
Altimmune narrowed its annual losses by 45% to negative $0.74 per share and beat earnings estimates in all four quarters.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More positive than 79% of claims this week
Altimmune shares surged 35.4% over the past week, driven by a sharp increase in positive retail investor sentiment on Reddit.
More positive than 66% of claims this week
Which stocks this story touches
More positive than 99% of ticker scores this week
FDA granted Breakthrough Therapy Designation for pemvidutide and the company beat earnings estimates.
More positive than 96% of ticker scores this week
Shares are up 2,236% over the past year.
More negative than 83% of ticker scores this week
Shares plunged 22% at market open on Monday.
More positive than 77% of ticker scores this week
Shares rose 4.4% this week coinciding with a shift in retail investor sentiment.
More positive than 71% of ticker scores this week
Shares are up 12%.
Near neutral — 92% of ticker scores this week are stronger
Mentioned as a dominant market leader with strong growth, but used primarily as a valuation benchmark for Altimmune.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Reuters
43m ago
−45.0%
Price is moving against the score
$2.96 vs $5.38 close before publication (Jan 22) · not market-adjusted
ALT chart →
